Skip to main content

Diabetes Drug News

Diabetes Drugs are responsible for helping to decrease blood sugar levels so that you can try to stay in a healthier range and help avoid serious complications.

Metformin     Insulin     SGLT-2     GLP-1     DPP-4     Combo drugs     Sulfonylureas     TZDs

Kelly’s take on the maddeningly slow FDA approval process and why things are probably getting better.
On June 16, FDA officials provided an update on its safety review of Takeda’s Actos (pioglitazone), announcing that going forward, prescribing information for Actos will...
In previous issues, we’ve documented the arduous journey of Orexigen’s anti-obesity drug Contrave through the regulatory process. In December, an FDA Advisory Committee...
In June, Insulet announced the acquisition of Neighborhood Diabetes, a medical equipment distributor that specializes in consumer sales of diabetes supplies. The company...
In late June, the European Medicines Agency (EMA) approved Amylin/Eli Lilly/Alkermes’ once-weekly injectable drug Bydureon for type 2 diabetes. We’ve been waiting for...
Earlier in April, Biodel management updated the timeline for the development of its ultra-rapid-acting insulin candidates. As a reminder, in October 2010 the company's...
People with diabetes are at significantly increased risk for kidney impairment or kidney failure. Kidney disease can complicate the treatment of type 2 diabetes because...
In mid-April, the European Medicine Agency's Committee for Medicinal Products for Human Use (a committee called the "CHMP") recommended that Amylin/Lilly/Alkermes' once-...
In a recent study, Novo Nordisk's next-generation basal insulin degludec was found to cause less hypoglycemia than Lantus. In early May, Novo Nordisk announced the...
Puzzled by the recent FDA decisions? Dr. Sanjay Kaul discusses the regulatory environment for diabetes and obesity medications.
Earlier this month, the FDA approved the once-daily oral drug Tradjenta (Boehringer Ingelheim and Eli Lilly’s linagliptin) for type 2 diabetes. Tradjenta belongs to the...
Kelly muses on the future of GLP-1 agonists and bariatric surgery.
For type 2 patients, the use of GLP-1 agonists (such as Victoza and Byetta ) can often lead to significant improvements in blood glucose control and weight loss with...
Novo Nordisk’s once daily GLP-1 agonist Victoza (above) provided slightly better improvements in blood glucose control than Amylin/Eli Lilly/ Alkermes’s once weekly GLP-...
Novo Nordisk’s “next-generation” basal insulin degludec. Novo Nordisk has released promising data from a 7,000-participant clinical trial for its next-generation basal...
In a major setback for MannKind Corporation ’s inhalable insulin therapy, Afrezza, the FDA is requiring the company to conduct two additional clinical trials of the...
Earlier this month, Eli Lilly and the German pharmaceutical Boehringer Ingelheim (BI) announced a major partnership to co-develop and co-commercialize several of their...
In late 2010, Merck announced that it had acquired SmartCells, a small Massachusetts-based company that is developing a smart insulin product aptly named SmartInsulin...
In early November, Kombiglyze, a pill combining DPP-4 inhibitor Onglyza and metformin, was approved by the FDA for type 2 diabetes. Onglyza was approved in July 2010...
Medical technology manufacturer Valeritas announced earlier this month that it received FDA clearance to market its V-Go Disposable Insulin Delivery Device, which...

Pages